Sir,

The hereditary spastic paraplegias (HSPs) are a heterogeneous group of neurodegenerative disorders. Few epidemiological studies of HSPs have been done to date. The estimated prevalence is 3--10 cases/100,000 population in Europe.\[[@ref1]\]

The diagnostic clinical findings are spasticity and pyramidal weakness in lower limbs, with hyperreflexia and extensor plantar responses. The genetics of HSPs is complex, and all modes of inheritance (autosomal dominant \[AD\], autosomal recessive \[AR\], and X-linked \[XL\] recessive) have been described.\[[@ref2]\] AR HSPs are more frequent in consanguineous populations with a prevalence of 0.6/100,000 in Norway and up to 5.75/100,000 in Tunisia.\[[@ref2][@ref3]\] HSP type 35 is an AR form of HSPs caused by mutations in the fatty acid 2-hydroxylase (*FA2H*) gene at 1\'q21-q23 chromosome.\[[@ref2]\]

In the literature, a few cases have been reported with HSP type 35.\[[@ref3][@ref4][@ref5][@ref6]\] Here, we report HSP type 35 case of Turkish origin with a novel homozygous mutation in *FA2H* gene, presented with progressive gait disturbance and cognitive impairment.

A 16-years-old boy was admitted to our hospital because of progressive difficulty in walking, unsteady gait, cognitive impairment, and hand tremor. He had normal motor and intellectual development until the age of 10 years when gait disturbance and balance problems first appeared. Five years later, he began to show deterioration in academic skills. The patient was diagnosed with cerebral palsy because of these complaints in another hospital. The parents were consanguineous, and there was no family history of neurologic disease. He was born at term and had no neonatal problems. He had healthy two older sisters. Pedigree is shown in [Figure 1](#F1){ref-type="fig"}.

![Pedigree of the patient](AIAN-21-335-g001){#F1}

Neurological examination revealed mild cognitive impairment and spasticity. The deep tendon reflexes were increased in lower limbs, with ankle clonus and bilateral Babinski signs. He had muscle weakness of Grade 4/5 distally in both lower limbs and had mild bilateral foot drop, pes cavus deformities, and muscular atrophy. Ophthalmologic examination and the other physical examination were normal.

Complete blood count, serum biochemistry, lipid profile, thyroid function tests, and serum Vitamin E and B12 levels were all normal. Brain magnetic resonance imaging (MRI) showed bilateral symmetrical hyperintense lesions in the periventricular white matter in T-weighted images \[[Figure 2](#F2){ref-type="fig"}\]. Nerve conduction studies revealed demyelinating form of polyneuropathy. Based on the clinical findings and nerve conduction studies, the patient was thought as HSP.

![Cerebral magnetic resonance imaging showed bilateral symmetrical hyperintense lesions in the periventricular white matter](AIAN-21-335-g002){#F2}

Clinical exome sequencing analysis was performed in the patient using TruSight One kits (Illumina Inc., San Diego, CA, USA). As a result of the clinical exome analysis, we identified a novel missense homozygous mutation at the *FA2H* gene (c.130C\>T p. Pro44Ser p. P44S) which has not been reported previously. The mutation found was considered to be highly probable cause of disease according to in silico analysis (Sorting Tolerant From Intolerant, <http://sift.jcvi.org> and Mutation Taster, <http://www.mutationtaster.org>). Additional family screening revealed that both parents had heterozygous mutation. We confirmed that the patient was HSP type 35 due to clinical and genetically evaluation.

To date, 70 different gene loci associated with HSP were identified, involving XL, AR, AD, and maternal inheritance.\[[@ref2]\]

AR spastic paraplegia-35 (SPG35) is a characterized by childhood onset of gait difficulties due to progressive spastic paraparesis, dysarthria, and mild cognitive decline associated with leukodystrophy on brain imaging. Other variable neurologic features, such as dystonia, optic atrophy, and seizures, may also occur.\[[@ref3][@ref4]\]

SPG35 is caused by mutations in the *FA2H* gene located on chromosome 16q23. *FA2H* was first described in 2008 as a rare leukodystrophy gene causing spasticity and dystonia.\[[@ref7]\] In addition, *FA2H* gene has been shown to be associated with neurodegeneration with brain iron accumulation, thus expanding the phenotype. This phenotypic spectrum of disorders was then referred as fatty acid hydrolase-associated neurodegeneration (FAHN).\[[@ref8]\]

*FA2H* gene encodes *FA2H*, a 372-amino-acid-long membrane-bound protein incorporated into the ceramide species which is necessary for the production of normal myelin. It contains two conserved domains, a cytochrome b5-like heme-binding domain, spanning residues 15--85 and responsible for the redox activity of *FA2H*, and a sterol desaturase domain at residues 210--367.\[[@ref9]\]

To date, approximately 51 patients from 19 families have been reported in the literature.\[[@ref5]\] Cao *et al*.\[[@ref4]\] reported two siblings born to nonconsanguineous parents, who possess several typical clinical features of SPG35, a subtype of FAHN, owing to novel *FA2H* missense mutation. Two affected siblings had typical clinical features of SPG35. For the two siblings, brain MRI showed progressive leukoencephalopathy with cortical, cerebellar, and brainstem atrophy. Thinning of the corpus callosum was also noted. Soehn *et al*.\[[@ref5]\] described four novel homozygous *FA2H* mutations in four nonconsanguineous families with SPG35. All four children presented with a complicated form of HSP with tetraspasticity and additional symptoms including limb ataxia (3/4), mild cognitive deficits (3/4), and extrapyramidal involvement (3/4). In another case, Liao *et al*.\[[@ref3]\] reported three novel *FA2H* gene mutations in two unrelated Chinese families with SPG35. Bektaş *et al*.\[[@ref6]\] described a 5-year-old boy presenting with spastic paraplegia without seizure, neuropathy, cognitive impairment, speech disturbance, and optic atrophy in Turkey. Their patient was rapid progressive spastic paraplegia, and he was early loss of ambulation. Our case had gait difficulties due to progressive spastic paraparesis, hand tremor, mild cognitive deficits, and additional findings including demyelinating form of polyneuropathy. He had no optic atrophy and cerebellar dysfunction.

Recently, identification of the neurodegeneration with brain iron accumulation expanded the phenotypic spectrum of the disorders associated with the *FA2H* gene mutation.\[[@ref8]\] Brain iron accumulation was not shown in the patient.

Bektaş *et al*.\[[@ref6]\] detected a novel homozygous mutation c. 160_169 dup (p. Asp57Glyfs\*48) in the gene encoding *FA2H* in their case in Turkey. We detected novel homozygous mutation c.130C\>T (p. Pro44Ser) (p. P44S) in the *FA2H* gene. Furthermore, the patient had demyelinating form of polyneuropathy which has not been reported in SPG35 previously. [Table 1](#T1){ref-type="table"} presents the analysis of cases of SPG35 from the literature and the patient.

###### 

The analysis of cases of hereditary spastic paraplegia type 35 from the literature and our patient
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In conclusion, HSPs are clinically and genetically heterogeneous disorders characterized by lower limb spasticity and weakness. SPG35 should be included in the differential diagnosis of lower limb spasticity and weakness when additional ataxia, mild cognitive deficits, and extrapyramidal involvement.
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